Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004102427> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2004102427 endingPage "124" @default.
- W2004102427 startingPage "123" @default.
- W2004102427 abstract "Movement disorder is a prominent feature of Huntington’s disease and consists of involuntary and voluntary components as well as associated bradykinesia. Pharmacological treatment is problematic because of the side effects of the drugs used, which may further compromise cognitive functioning and mobility. Patients are often not subjectively aware of their movements but can be considerably disabled by them and carers are often distressed and enquire about treatment options. If drug treatment is considered it is important to achieve the maximum improvement in movements with the minimum of negative side effects. This paper describes the effect of olanzapine on movements when other treatment options had been ineffective or limited by side effects.Huntington’s disease is a hereditary progressive neurodegenerative disorder. It consists of a triad of symptoms comprising motor, psychological, and cognitive abnormalities. The motor component consists of involuntary choreiform movements and increasing difficulties with voluntary movement. The degree of the involuntary movements is variable but in some patients can be very marked. Progression over time of the movement disorder in Huntington’s disease can be monitored using the quantitative neurological examination (QNE). This measure has three subscales, an eye movement scale, a motor impairment scale (MIS) quantifying voluntary movement, and a chorea scale measuring involuntary movement.1 2 Pharmacological control of the symptoms has been shown to be effective with dopamine antagonists,3 4 but their use is limited because of the side effects. Clinically the most problematic of these are sedation, cognitive slowing, increased mobility problems, and hypotension. The inability of traditional dopamine antagonists to improve functional capacity, despite ameliorating chorea, is possibly due to suppression of voluntary motor activity.4 5Tardive …" @default.
- W2004102427 created "2016-06-24" @default.
- W2004102427 creator A5052274982 @default.
- W2004102427 date "1999-07-01" @default.
- W2004102427 modified "2023-10-14" @default.
- W2004102427 title "The use of olanzapine for movement disorder in Huntington's disease: a first case report" @default.
- W2004102427 cites W1991867764 @default.
- W2004102427 cites W2041863334 @default.
- W2004102427 cites W2060432509 @default.
- W2004102427 cites W237141987 @default.
- W2004102427 cites W2407234902 @default.
- W2004102427 cites W97732542 @default.
- W2004102427 doi "https://doi.org/10.1136/jnnp.67.1.123" @default.
- W2004102427 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1736408" @default.
- W2004102427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10454874" @default.
- W2004102427 hasPublicationYear "1999" @default.
- W2004102427 type Work @default.
- W2004102427 sameAs 2004102427 @default.
- W2004102427 citedByCount "36" @default.
- W2004102427 countsByYear W20041024272013 @default.
- W2004102427 countsByYear W20041024272014 @default.
- W2004102427 countsByYear W20041024272016 @default.
- W2004102427 countsByYear W20041024272018 @default.
- W2004102427 countsByYear W20041024272021 @default.
- W2004102427 crossrefType "journal-article" @default.
- W2004102427 hasAuthorship W2004102427A5052274982 @default.
- W2004102427 hasBestOaLocation W20041024271 @default.
- W2004102427 hasConcept C107038049 @default.
- W2004102427 hasConcept C118552586 @default.
- W2004102427 hasConcept C126322002 @default.
- W2004102427 hasConcept C142362112 @default.
- W2004102427 hasConcept C15744967 @default.
- W2004102427 hasConcept C2776412080 @default.
- W2004102427 hasConcept C2776619155 @default.
- W2004102427 hasConcept C2778261627 @default.
- W2004102427 hasConcept C2779134260 @default.
- W2004102427 hasConcept C2780226923 @default.
- W2004102427 hasConcept C2780647506 @default.
- W2004102427 hasConcept C71924100 @default.
- W2004102427 hasConceptScore W2004102427C107038049 @default.
- W2004102427 hasConceptScore W2004102427C118552586 @default.
- W2004102427 hasConceptScore W2004102427C126322002 @default.
- W2004102427 hasConceptScore W2004102427C142362112 @default.
- W2004102427 hasConceptScore W2004102427C15744967 @default.
- W2004102427 hasConceptScore W2004102427C2776412080 @default.
- W2004102427 hasConceptScore W2004102427C2776619155 @default.
- W2004102427 hasConceptScore W2004102427C2778261627 @default.
- W2004102427 hasConceptScore W2004102427C2779134260 @default.
- W2004102427 hasConceptScore W2004102427C2780226923 @default.
- W2004102427 hasConceptScore W2004102427C2780647506 @default.
- W2004102427 hasConceptScore W2004102427C71924100 @default.
- W2004102427 hasIssue "1" @default.
- W2004102427 hasLocation W20041024271 @default.
- W2004102427 hasLocation W20041024272 @default.
- W2004102427 hasLocation W20041024273 @default.
- W2004102427 hasLocation W20041024274 @default.
- W2004102427 hasOpenAccess W2004102427 @default.
- W2004102427 hasPrimaryLocation W20041024271 @default.
- W2004102427 hasRelatedWork W1543664114 @default.
- W2004102427 hasRelatedWork W1995615629 @default.
- W2004102427 hasRelatedWork W2004102427 @default.
- W2004102427 hasRelatedWork W2022333985 @default.
- W2004102427 hasRelatedWork W2022605758 @default.
- W2004102427 hasRelatedWork W2560562774 @default.
- W2004102427 hasRelatedWork W2748952813 @default.
- W2004102427 hasRelatedWork W2899084033 @default.
- W2004102427 hasRelatedWork W630272210 @default.
- W2004102427 hasRelatedWork W2295048429 @default.
- W2004102427 hasVolume "67" @default.
- W2004102427 isParatext "false" @default.
- W2004102427 isRetracted "false" @default.
- W2004102427 magId "2004102427" @default.
- W2004102427 workType "article" @default.